Klabex Tablet 500 mg
৳ 35.19
Adults:
Pharyngitis/Tonsillitis: 250 mg for 10 days
Acute maxillary sinusitis: 500 mg for 14 days
Chronic bronchitis: 250 – 500 mg for 7-14 days
Pneumonia: 250 mg for 7-14 days
Uncomplicated skin and skin structure infections: 250 mg for 7-14 days
Community-acquired upper and lower respiratory tract infections: 250 – 500 mg for 5-14 days
Children:
Body weight under 8 kg: 7.5 mg/kg twice daily
Body weight of 8-11 kg (1-2 years): 62.5 mg twice daily
Body weight of 12-19 kg (3-6 years): 125 mg twice daily
Body weight of 20-29 kg (7-9 years): 187.5 mg twice daily
Body weight of 30-40 kg (10-12 years): 250 mg twice daily
Eradication of H. pylori in patients with duodenal ulcers:
Triple Therapy: Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be given with amoxycillin 1000mg twice daily.
Triple Therapy: Clarithromycin (500mg) twice daily and lansoprazole 30mg twice daily should be given with metronidazole 400mg twice daily.
Triple Therapy: Clarithromycin (500mg) twice daily and omeprazole 40mg daily should be given with amoxycillin 1000mg twice daily or metronidazole 400mg twice daily.
Triple Therapy: Clarithromycin (500mg) twice daily should be given with amoxycillin 1000mg twice daily and omeprazole 20mg daily.
Dual Therapy: The usual dose of Clarithromycin is 500mg three times daily for 14 days.
Clarithromycin should be administered with oral omeprazole 40mg once daily. The pivotal study was conducted with omeprazole 40mg once daily for 28 days. Supportive studies have been conducted with omeprazole 40mg once daily for 14 days.
Clarithromycin acts by inhibiting microsomal protein synthesis in susceptible organisms mainly by binding to the donor site on the 50S sub- unit of the bacterial ribosome and preventing translocation to that site.
Clarithromycin is active against most Gram-positive bacteria and Chlamydia, some Gram-negative bacteria and Mycoplasmas.
Clarithromycin’s activity is the same as, or greater than, that of erythromycin in vitro against most Gram-positive bacteria. Clarithromycin is more acid stable than erythromycin and therefore, is better tolerated. Clarithromycin has twice the activity of erythromycin against H. influenzae. Most species of Gram-negative bacteria are resistant to clarithromycin because of failure to penetrate to the target.
Related products
